Ayaka Asakawa

Dr. Ayaka Asakawa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
MOMasayuki Okui
Masayuki Okui
TYTakashi Yamamichi
Takashi Yamamichi
AAAyaka Asakawa
Ayaka Asakawa
MHMasahiko Harada
Masahiko Harada
MSMakoto Saito
Makoto Saito
HHHirotoshi Horio
Hirotoshi Horio

Verified
Journal Article
Open access
PDF file
HSHajime Shinohara
Hajime Shinohara
MKMaki Kobayashi
Maki Kobayashi
KHKumiko Hayashi
Kumiko Hayashi
DNDaichi Nogawa
Daichi Nogawa
AAAyaka Asakawa
Ayaka Asakawa
KYKouhei Yamamoto
Kouhei Yamamoto
Tumor-associated macrophages (TAMs) and abnormalities in cancer cells affect cancer progression and response to therapy. TAMs are a major component of the tumor microenvironment (TME) in breast cancer, with their invasion affecting clinical outcomes. Programmed death-ligand 1 (PD-L1), a target of immune checkpoint inhibitors, acts as a suppressive signal for the surrounding immune system; however, its expression and effect on TAMs and the clinical outcome in breast cancer are unknown. In this study, we used high-throughput multiple immunohistochemistry to spatially and quantitatively analyze TAMs. We subjected 81 breast cancer specimens to immunostaining for CD68, CD163, PD-1, PD-L1, CD20, and pan-CK. In both stromal and intratumoral areas, the triple-negative subtype had significantly more CD68/CD163, CD68/PD-L1, and CD163/PD-L1 double-positive cells than the estrogen receptor (ER)/progesterone receptor (PR) subtype. Interestingly, a higher number of CD68+/PD-L1+/CK-/CD163- TAMs in the intratumoral area was correlated with a favorable recurrence rate (p = 0.048). These findings indicated that the specific subpopulation and localization of TAMs in the TME affect clinical outcomes in breast cancer.

6 May 2021 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
PDF file
AAAyaka Asakawa
Ayaka Asakawa
HIHironori Ishibashi
Hironori Ishibashi
YMYusuke Matsuyama
Yusuke Matsuyama
TFTakeo Fujiwara
Takeo Fujiwara
MKMasashi Kobayashi
Masashi Kobayashi
KOKenichi Okubo
Kenichi Okubo
We investigated whether preoperative nutritional indicators predicted the prognosis for patients with early-stage non-small cell lung cancer. Data for stage I or stage IIA non-small cell lung cancer without lymph node metastasis patients who received anatomical lung resection and were followed-up at least five years after surgery (n = 286) were analyzed. We calculated geriatric nutritional risk index, prognostic nutritional index, controlling nutritional status score, and modified Glasgow prognostic score. Multivariate Cox proportional hazard model adjusting for age, BMI, complication, pathological stage, histology of squamous cell carcinoma, T factor, diffusing capacity for carbon monoxide, surgery and smoking status was fitted to evaluate the association between these nutritional indicators and mortality and recurrence within five years. After adjusted for covariates other than type of surgery and diffusing capacity for carbon monoxide, controlling nutritional status of ≥3 was significantly associated with mortality (hazard ratio (HR) = 2.68, 95% confidence interval (CI) = 1.02, 7.01). The association remained marginally significant by adjusting for type of surgery and diffusing capacity for carbon monoxide (HR = 2.44, 95% CI = 0.92, 6.45). controlling nutritional status of ≥3 was significantly associated with recurrence (HR = 2.60; 95% CI: 1.20, 5.61) after adjusting for all covariates. Other nutritional indices did not predict the prognosis in multivariate analysis. Preoperative high controlling nutritional status score was marginally and significantly associated with mortality and recurrence of non-small cell lung cancer patients after lung resection.

5 April 2017 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
MOMasayuki Okui
Masayuki Okui
TYTakashi Yamamichi
Takashi Yamamichi
AAAyaka Asakawa
Ayaka Asakawa
MHMasahiko Harada
Masahiko Harada
HHHirotoshi Horio
Hirotoshi Horio
Masayuki Okui, M.D., Takashi Yamamichi, M.D., Ayaka Asakawa, M.D., Masahiko Harada, M.D., Hirotoshi Horio, M.D.. Korean J Thorac Cardiovasc Surg 2017;50:119-22. https://doi.org/10.5090/kjtcs.2017.50.2.119

2 December 2023 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
AAAyaka Asakawa
Ayaka Asakawa
HIHironori Ishibashi
Hironori Ishibashi
SBShunichi Baba
Shunichi Baba
KSKatsutoshi Seto
Katsutoshi Seto
RWRyo Wakejima
Ryo Wakejima
KOKenichi Okubo
Kenichi Okubo

4 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AAAyaka Asakawa
Ayaka Asakawa
RYRyoto Yoshimoto
Ryoto Yoshimoto
MKMaki Kobayashi
Maki Kobayashi
NINanae Izumi
Nanae Izumi
TMTakanori Maejima
Takanori Maejima
KYKouhei Yamamoto
Kouhei Yamamoto
Lung squamous cell carcinoma (LSCC) is refractory to various therapies for non-small cell cancer; therefore, new therapeutic approaches are required to improve the prognosis of LSCC. Although immunotherapies targeting B7 family molecules were explored as treatments for several cancer types, the expression and significance of B7-H3 in the tumor microenvironment (TME) and its relationship with other immune checkpoint molecules have not yet been investigated in detail. We used high-throughput quantitative multiplex immunohistochemistry to examine B7-H3 expression in the TME. We investigated the relationship between B7-H3 expression and prognosis as well as changes in the TME with B7-H3 expression using 110 surgically resected pathological specimens retrospectively. We examined the correlation between B7-H3 and programmed cell death-ligand 1 (PD-L1) expression in single cells. High B7-H3 expression in tumor cells was associated with a better prognosis and a significant increase in the number of CD163+PD-L1+ macrophages. Quantitative analysis revealed that there is a positive correlation between B7-H3 and PD-L1 expression in tumor and stromal cells, as well as in intratumoral tumor-infiltrating lymphocytes and tumor-associated macrophages in the same cells. CD68+, CD163+, and CK+ cells with PD-L1+ phenotypes had higher B7-H3 expression compared to PD-L1− cells. Our findings demonstrate a correlation between B7-H3 and PD-L1 expression in the same cells, indicating that therapies targeting B7-H3 could provide additional efficacy in patients refractory to PD-L1-targeting therapies.